Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Axonics, Inc.

Market Cap 362.77Cr 313.33Cr 288.73Cr 270.27Cr 506.5Cr 34TCr 514.34Cr 3.41TCr 1.33TCr 17TCr 1.36TCr 1.33TCr 58TCr P/E Ratio 2022
-48.9x
P/E Ratio 2023 -502x
Enterprise Value 331.04Cr 285.92Cr 263.47Cr 246.62Cr 462.19Cr 31TCr 469.35Cr 3.11TCr 1.21TCr 15TCr 1.24TCr 1.22TCr 53TCr EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/10/2013
Director of Finance/CFO 41 02/10/2023
Chief Operating Officer 47 01/08/2018
Director TitleAgeSince
Director/Board Member 69 01/02/2018
Chairman 55 29/04/2020
Director/Board Member 74 08/04/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.10% - - 362.77Cr
+2.15%+2.14%-17.25%+10.81% 12TCr
-0.31%-1.22%+3.56%-4.71% 1.29TCr
+2.05%+1.45%+29.93%+90.52% 744.45Cr
+1.87%-4.66%-46.88%-69.45% 419.91Cr
+2.06%+4.10%+11.98%+37.03% 254.61Cr
+5.46%+10.04%-15.76%-14.08% 179.62Cr
+1.67%-5.73%+5.08%-9.77% 165.98Cr
-8.89%-10.79%+152.96%+119.71% 136.83Cr
Average +0.67%+0.88%+15.45%+20.01% 1.9TCr
Weighted average by Cap. +1.82%+1.76%-11.70%+12.08%

Financials

2022 2023
Net sales 27Cr 24Cr 22Cr 20Cr 38Cr 2.6TCr 39Cr 257.22Cr 100.29Cr 1.27TCr 102.72Cr 100.53Cr 4.38TCr 37Cr 32Cr 29Cr 27Cr 51Cr 3.48TCr 52Cr 344.32Cr 134.24Cr 1.7TCr 137.5Cr 134.57Cr 5.87TCr
Net income -5.97Cr -5.16Cr -4.75Cr -4.45Cr -8.33Cr -567.43Cr -8.46Cr -56Cr -22Cr -276.19Cr -22Cr -22Cr -956.31Cr -60.88L -52.58L -48.45L -45.36L -85L -58Cr -86.32L -5.72Cr -2.23Cr -28Cr -2.28Cr -2.24Cr -98Cr
Net Debt -35Cr -30Cr -28Cr -26Cr -49Cr -3.31TCr -49Cr -327.13Cr -127.55Cr -1.61TCr -130.64Cr -127.86Cr -5.58TCr -32Cr -27Cr -25Cr -24Cr -44Cr -3.02TCr -45Cr -298.23Cr -116.28Cr -1.47TCr -119.1Cr -116.56Cr -5.08TCr
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!